BDSX Q3 2024 Earnings — Biodesix, Inc. Revenue & Financial Results | Market Cap Arena

BDSXBiodesix, Inc.

$151M

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$18M+34.5% YoY

Gross Profit

$14M77.0% margin

Operating Income

-$9M-47.3% margin

Net Income

-$10M-56.5% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$103M

Total Liabilities

$75M

Stockholders' Equity

$28M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$13M	+34.5%
Gross Profit	$14M	$10M	+36.2%
Operating Income	-$9M	-$7M	-19.8%
Net Income	-$10M	-$11M	+6.3%

Revenue Segments

Diagnostic Tests

$17M100%